Antibody-Drug Conjugates (ADCs) represent one of the most advanced classes of targeted therapeutics, combining the specificity of monoclonal antibodies with the potency of cytotoxic drugs. As ADC innovation accelerates, patent protection – particularly the accurate preparation of sequence listings – has become a critical component of intellectual property strategy.
This article outlines best practices for preparing ADC sequence listings for patent filing, with a focus on regulatory compliance, clarity and global harmonization.
Understanding ADCs in the Patent Context
An ADC typically consists of three key components:
- Monoclonal antibody (mAb): Targets specific antigens on diseased cells
- Linker: Chemically connects the antibody and drug payload
- Cytotoxic payload (drug): Kills the targeted cell once internalized
From a patent perspective, the antibody sequence (heavy and light chains), engineered variants and sometimes linker-related peptides are central to sequence disclosure requirements.
Because ADCs often involve complex biologics, accurate sequence listing is essential for enabling disclosure and enforceability.
What Is a Sequence Listing?
A sequence listing is a structured representation of biological sequences included in a patent application. It ensures that nucleotide and amino acid sequences are:
- Uniformly formatted
- Machine-readable
- Searchable across global patent databases
Patent offices such as the United States Patent and Trademark Office and other international offices require standardized sequence listings for biologics-related inventions.
Regulatory Standard: WIPO ST.26
Modern sequence listings are governed by the WIPO ST.26 standard, established by the World Intellectual Property Organization.
Key features include:
- XML-based structured format
- Mandatory for all patent applications with sequence disclosures filed after the transition date (2022 onward in many jurisdictions)
- Standardized representation of amino acid and nucleotide sequences
- Improved interoperability between patent offices globally
For ADC patents, compliance with ST.26 is essential because antibody sequences often include multiple engineered variants and substitutions that must be precisely documented.
What Must Be Included in ADC Sequence Listings?
When filing ADC-related patents, sequence listings should typically include:
1. Antibody Sequences
- Heavy chain amino acid sequences
- Light chain amino acid sequences
- Variable region sequences (VH/VL)
- Framework and CDR regions (if applicable)
2. Engineered Variants
- Humanized or affinity-matured variants
- Mutated residues for stability or binding improvement
- Bispecific antibody sequences (if applicable)
3. Optional Biologically Relevant Sequences
- Signal peptides
- Fusion tags (if part of construct)
- Linker peptides (when peptide-based rather than chemical)
Note: Chemically synthesized linkers and small-molecule payloads are generally not included in sequence listings unless they involve peptide sequences.
Best Practices for ADC Sequence Listing Preparation
1. Ensure Sequence Accuracy at the Source
Errors in antibody sequences can invalidate or weaken a patent. Best practices include:
- Confirming sequences with validated experimental data
- Using consistent numbering schemes (e.g., Kabat, IMGT)
- Verifying mutations and engineered modifications carefully
2. Follow ST.26 Formatting Strictly
Non-compliance with WIPO ST.26 often leads to filing delays or corrections. Key rules:
- Use correct XML tagging structure
- Assign proper sequence identifiers (SEQ ID NO)
- Clearly define sequence type (amino acid or nucleotide)
- Avoid deprecated ST.25 formats in new filings
3. Clearly Define Sequence Functionality
Patent examiners must understand the role of each sequence. It is good practice to:
- Annotate antigen-binding regions
- Identify functional domains (Fab, Fc, etc.)
- Specify modifications affecting binding affinity or effector function
4. Maintain Consistency Across the Patent Specification
Sequence listings must match the written patent description exactly:
- SEQ ID references must align with figures and claims
- No discrepancies between claims and sequence listing
- Ensure uniform terminology across documents
5. Consider Multi-Jurisdiction Filing Requirements
ADC patents are typically filed globally. While ST.26 is harmonized, filing nuances may vary across jurisdictions administered by bodies like:
- United States Patent and Trademark Office
- European Patent Office (EPO)
- Japan Patent Office (JPO)
Early coordination helps avoid reformatting delays during national phase entry.
6. Avoid Over-Disclosure of Non-Essential Sequences
Only include sequences that are necessary for:
- Claim support
- Enablement
- Functional definition of the invention
Excessive or irrelevant sequence data can complicate examination and increase rejection risk.
Common Mistakes in ADC Sequence Listings
- Mixing up heavy and light chain identifiers
- Incorrect SEQ ID numbering across documents
- Failing to update sequences after engineering changes
- Including chemical linker structures as amino acid sequences
- Using outdated formatting standards (ST.25 instead of ST.26)
Strategic Importance of High-Quality Sequence Listings
For ADC developers, a well-prepared sequence listing provides:
- Stronger patent enforceability
- Reduced examination delays
- Improved global filing consistency
- Better protection against biosimilar competition
Given the competitive ADC landscape, precision in sequence disclosure is not just administrative – it is a core element of intellectual property strategy.
Conclusion
ADC patents sit at the intersection of complex biologics and stringent regulatory requirements. Proper preparation of sequence listings under WIPO ST.26 ensures that antibody structures are clearly, consistently and globally recognized.
By following best practices – accurate sequence validation, strict formatting compliance and careful alignment with patent claims – innovators can significantly strengthen their ADC intellectual property position and reduce filing risks across jurisdictions.